Why Tevogen Bio Holdings Stock Is Moving Higher Today
Why Tevogen Bio Holdings Stock Is Moving Higher Today
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares are rising Monday after the company secured up to $50 million of financing from an existing investor.
周一，Tevogen Bio Holdings Inc.（纳斯达克股票代码：TVGN）股价上涨，此前该公司从现有投资者那里获得了高达5000万美元的融资。
What Happened: After the market close on Friday, Tevogen announced that it entered into a binding term sheet agreement with an existing investor to secure up to $50 million of financing.
发生了什么：周五收盘后，Tevogen宣布与现有投资者签订了具有约束力的条款表协议，以获得高达5000万美元的融资。
The financing is aimed at supporting continued research and development efforts for Tevogen's TVGN 489. In addition, the financing will be utilized to start clinical trials for virally induced cancers and multiple sclerosis.
这笔资金旨在支持Tevogen的TVGN 489的持续研发工作。此外，这笔资金将用于启动病毒诱发的癌症和多发性硬化症的临床试验。
"We strongly believe Tevogen's business model of efficient operations and innovative thinking allows us to meaningfully expand our R&D efforts and investments in Tevogen AI with the support of this additional financing. I'm pleased we are taking this significant step to help patients by providing affordable and accessible personalized T cell therapies for large patient populations." said Dr. Ryan Saadi, CEO of Tevogen.
“我们坚信，Tevogen的高效运营和创新思维的商业模式使我们能够在这笔额外融资的支持下，有意义地扩大对Tevogen AI的研发工作和投资。我很高兴我们正在采取这一重要步骤，通过为大量患者群体提供负担得起且可获得的个性化T细胞疗法来帮助患者。” Tevogen首席执行官瑞安·萨迪博士说。
Related Link: Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
相关链接：为什么JanOne股票交易价格上涨了19％；以下是20只股票，盘前走势
The financing contains a $36 million line of credit from an existing investor and $14 million in private placement. The line of credit grants Tevogen access to $1 million per month at an interest rate of either the daily secured overnight financing rate plus 2% or 7% accruing quarterly, depending on which is lower.
该融资包含来自现有投资者的3,600万美元信贷额度和1400万美元的私募配售。信贷额度使Tevogen每月可获得100万美元的利率，利率为每日有担保隔夜融资利率加上2％或每季度应计7％，视哪个较低者而定。
"Our continued investment emphasizes our conviction in Tevogen, its leadership and novel technology. Tevogen's cost-effective business model and the promise of commercial success make this a compelling transaction," said investor Dr. Manmohan Patel, who is taking part in the financing transaction.
“我们的持续投资凸显了我们对Tevogen、其领导地位和新技术的信念。参与融资交易的投资者曼莫汉·帕特尔博士说，Tevogen具有成本效益的商业模式和商业成功的前景使这笔交易成为一项引人注目的交易。
Price Action: According to Benzinga Pro, Tevogen stock was trading 15.7% higher at $1.15 Monday morning.
价格走势：根据Benzinga Pro的数据，周一上午Tevogen股价上涨15.7％，至1.15美元。
Image: 2616931 from Pixabay
图片：来自 Pixabay 的 2616931